Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma

被引：1

作者：

Lai, Fei Ya ^{[1
]}

Clarke, Rachel ^{[1
]}

Cooper, Patrick ^{[2
]}

Stokes, John ^{[3
]}

Calvert, Paula ^{[1
]}

机构：

[1] Univ Hosp Waterford, Oncol Dept, Waterford, Ireland

[2] Univ Hosp Waterford, Radiol Dept, Waterford, Ireland

[3] Univ Hosp Waterford, Ophthalmol Dept, Waterford, Ireland

来源：

CASE REPORTS IN ONCOLOGY | 2023年 / 16卷 / 01期

关键词：

Cutaneous squamous cell carcinoma; Cutaneous oncology; Dermatology; Metastatic cutaneous squamous cell carcinoma; Immunotherapy; Immunotoxicities; Immune checkpoint inhibitors;

D O I：

10.1159/000533759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer. Surgery is usually curative; however, some locally advanced or metastatic CSCC may be unresectable. Current novel therapeutic options with immune checkpoint inhibition (ICI) of programmed-death receptor 1 (PD-1) such as cemiplimab and nivolumab have demonstrated promising and sustained results with good tolerability in patients with CSCC. This study looks at 2 cases of CSCC treated with cemiplimab and nivolumab, respectively, demonstrating dramatic response within 2 cycles with significant reduction in tumour size and minimal toxicities or adverse outcomes reported. Immunotherapy has shown positive results as an effective treatment option for unresectable, recurrent, or metastatic CSCC. It is currently approved for use in the USA and Europe.

引用

页码：1156 / 1165

页数：10

共 11 条

[1] Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab [J].

Chen, Alessandra ;

Ali, Nabilah ;

Boasberg, Peter ;

Ho, Allen S. .

JOURNAL OF CLINICAL MEDICINE, 2018, 7 (01)

[2] Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials [J].

Di Federico, Alessandro ;

Rizzo, Alessandro ;

Carloni, Riccardo ;

De Giglio, Andrea ;

Bruno, Riccardo ;

Ricci, Dalia ;

Brandi, Giovanni .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (04) :361-369

[3] Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches [J].

Fania, Luca ;

Didona, Dario ;

Di Pietro, Francesca Romana ;

Verkhovskaia, Sofia ;

Morese, Roberto ;

Paolino, Giovanni ;

Donati, Michele ;

Ricci, Francesca ;

Coco, Valeria ;

Ricci, Francesco ;

Candi, Eleonora ;

Abeni, Damiano ;

Dellambra, Elena .

BIOMEDICINES, 2021, 9 (02) :1-33

[4] Update on the Management of Cutaneous Squamous Cell Carcinoma [J].

Maubec, Eve .

ACTA DERMATO-VENEREOLOGICA, 2020, 100 :309-317

[5] PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma [J].

Migden, M. R. ;

Rischin, D. ;

Schmults, C. D. ;

Guminski, A. ;

Hauschild, A. ;

Lewis, K. D. ;

Chung, C. H. ;

Hernandez-Aya, L. ;

Lim, A. M. ;

Chang, A. L. S. ;

Rabinowits, G. ;

Thai, A. A. ;

Dunn, L. A. ;

Hughes, B. G. M. ;

Khushalani, N. I. ;

Modi, B. ;

Schadendorf, D. ;

Gao, B. ;

Seebach, F. ;

Li, S. ;

Li, J. ;

Mathias, M. ;

Booth, J. ;

Mohan, K. ;

Stankevich, E. ;

Babiker, H. M. ;

Brana, I. ;

Gil-Martin, M. ;

Homsi, J. ;

Johnson, M. L. ;

Moreno, V. ;

Niu, J. ;

Owonikoko, T. K. ;

Papadopoulos, K. P. ;

Yancopoulos, G. D. ;

Lowy, I. ;

Fury, M. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (04) :341-351

[6] A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma [J].

Munhoz, Rodrigo R. ;

Nader-Marta, Guilherme ;

de Camargo, Veridiana P. ;

Queiroz, Marcello M. ;

Cury-Martins, Jade ;

Ricci, Herminia ;

de Mattos, Marcela R. ;

de Menezes, Thiago A. F. ;

Machado, Guilherme U. C. ;

Bertolli, Eduardo ;

Barros, Milton ;

de Souza, Carina E. ;

Franke, Fabio ;

Ferreira, Fabio O. ;

Feher, Olavo ;

de Castro Jr, Gilberto .

CANCER, 2022, 128 (24) :4223-4231

[7] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J].

Rizvi, Naiyer A. ;

Hellmann, Matthew D. ;

Snyder, Alexandra ;

Kvistborg, Pia ;

Makarov, Vladimir ;

Havel, Jonathan J. ;

Lee, William ;

Yuan, Jianda ;

Wong, Phillip ;

Ho, Teresa S. ;

Miller, Martin L. ;

Rekhtman, Natasha ;

Moreira, Andre L. ;

Ibrahim, Fawzia ;

Bruggeman, Cameron ;

Gasmi, Billel ;

Zappasodi, Roberta ;

Maeda, Yuka ;

Sander, Chris ;

Garon, Edward B. ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Schumacher, Ton N. ;

Chan, Timothy A. .

SCIENCE, 2015, 348 (6230) :124-128

[8] Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis [J].

Rizzo, Alessandro ;

Cusmai, Antonio ;

Giovannelli, Francesco ;

Acquafredda, Silvana ;

Rinaldi, Lucia ;

Misino, Andrea ;

Montagna, Elisabetta Sara ;

Ungaro, Valentina ;

Lorusso, Mariagrazia ;

Palmiotti, Gennaro .

CANCERS, 2022, 14 (06)

[9] Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects [J].

Rizzo, Alessandro ;

Ricci, Angela Dalia ;

Lanotte, Laura ;

Lombardi, Lucia ;

Di Federico, Alessandro ;

Brandi, Giovanni ;

Gadaleta-Caldarola, Gennaro .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) :557-565

[10] Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis [J].

Santoni, Matteo ;

Rizzo, Alessandro ;

Kucharz, Jakub ;

Mollica, Veronica ;

Rosellini, Matteo ;

Marchetti, Andrea ;

Tassinari, Elisa ;

Monteiro, Fernando Sabino Marques ;

Soares, Andrey ;

Molina-Cerrillo, Javier ;

Grande, Enrique ;

Battelli, Nicola ;

Massari, Francesco .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (06) :1365-1379

← 1 2 →